Navigation Links
USP awards verified mark to Dr. Reddy's Laboratories, Ltd. ingredients
Date:10/2/2007

Rockville, Md., October 2, 2007 The United States Pharmacopeial Convention (USP) today announced the award of a specific verification mark, shown at the conclusion of this announcement, to two drug substances (Active Pharmaceutical Ingredients) manufactured by Dr. Reddys Laboratories, Ltd. in Hyderabad, India. The two drug substances are Ramipril and Finasteride. Dr. Reddys may now use this special mark on its certificate of analyses and other materials to signal to purchasers, regulatory bodies, official medicines control laboratories, independent testing bodies, and others that the two drug substances have undergone a rigorous and independent conformity assessment activity conducted under the auspices of USPs Pharmaceutical Ingredient Verification Program (PIVP). Dr. Reddys was the first manufacturer to enter the USP PIVP. Two more drug substances manufactured by Dr. Reddys are in the final stages of verification by USP.

USPs PIVP is a voluntary program that includes:

  • Evaluation of an ingredient manufacturers quality systems through an audit for compliance with Good Manufacturing Practices (GMPs, using ICH Q7 as the standard);

  • Review of manufacturing and quality control documents;

  • Laboratory testing of ingredient samples from USP-selected lots for compliance with a private or public monograph, including those available in the United States Pharmacopeia (USP);

  • Request for follow-on information such as post evaluation change in method or manufacturer that might alter the primary decision; and

  • Yearly re-evaluation through testing and other approaches.

USP has verification programs for dietary supplements and dietary supplement ingredients and, based on decisions of its Board of Trustees, expanded these programs last year to include pharmaceutical ingredients, both drug substances and excipients, said Roger L. Williams, M.D., USPs executive vice president and CEO. USP believes these programs are critically needed in a world with many thousands of manufacturers making many thousands of pharmaceutical ingredients. Dr. Williams said that many of these ingredients seldom if ever receive inspections, even in advanced countries, and many may be substandard or even counterfeit. While USPs effort is small, Williams noted that it represents a substantial commitment to work with manufacturers who wish to obtain independent documentation of the integrity of their work and the commitment of their employees. Dr. Williams also said that continued vigilance is needed to assure the quality of manufactured ingredients for medicines, even when an ingredient has been verified through USPs PIVP program. He noted that the PIVP mark is not intended to signal a well-manufactured drug product, which is the responsibility of a dosage form manufacturer working with a responsible regulatory agency.

Satish Reddy, COO and managing director of Dr. Reddy's Laboratories, stated, "This certification from a highly respectable body such as the USP is yet another veracious witness of quality systems that are internalised in the operations at Dr.Reddys. We will continue to work closely with USP to expand the coverage of this certification program in Dr. Reddys."

USP will provide a special certificate to Dr. Reddys at the CPhI trade show in Milan on October 2. The certificate will recognize Ramipril and Finasteride as the first drug substances to earn the USP verification mark for pharmaceutical ingredients.

USP looks forward to partnering with regulatory and compendial bodies around the world in advancing its pharmaceutical ingredients verification program. The conformity assessment activity embodied in USPs verification programs, including PIVP, not only assists manufacturers but also helps USP update monographs in USP and National Formulary and allied official USP Reference Standards (reference materials). Despite this opportunity, USP separates entirely the standards-setting activities of the Council of Experts from its PIVP and other verification programs to ensure the continued independence and objectivity of its standard-setting processes.


'/>"/>

Contact: Sandra Kim
sek@usp.org
301-816-8241
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. Prehistoric mystery organism verified as giant fungus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... annual Inventors Recognition Reception at Purdue Research Park of West Lafayette, ... in recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
Breaking Biology Technology: